ArticleCancers2022

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.

Yeejin Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.